Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr;195(4):2587-2596.
doi: 10.1007/s12010-021-03514-y. Epub 2022 Apr 21.

Progeria-a Rare Genetic Condition with Accelerated Ageing Process

Pratik Talukder  1 , Arunima Saha  2 , Sohini Roy  2 , Gargi Ghosh  2 , Debshikha Dutta Roy  2 , Snejuti Barua  2
Affiliations
Review

Progeria-a Rare Genetic Condition with Accelerated Ageing Process

Pratik Talukder et al. Appl Biochem Biotechnol. 2023 Apr.

Abstract

Progeria is a rare genetic disease which is characterised by accelerated ageing and reduced life span. There are differing types of progeria, but the classic type is Hutchinson-Gilford progeria syndrome (HGPS). Within a year of birth, people suffering from it start showing several features such as very low weight, scleroderma, osteoporosis and loss of hair. Their life expectancy is highly reduced and the average life span is around 14.6 years. Research is going on to understand the genetic and molecular level causes of this disease. Apart from that, several studies are also going on to discover therapeutic techniques and drugs to treat this disease but the success rate is very low. To gain a better understanding about research developments of progeria more experimental models, drugs and molecular technologies are under trial. Different important aspects and recent developments in epidemiology, genetic causes, symptoms, diagnosis and treatment options of progeria are discussed in this review.

Keywords: Clinical trials; Experimental models; Hutchinson-Gilford progeria syndrome (HGPS); Lamin A; Lonafarnib; Progerin; Translational.

PubMed Disclaimer

References

    1. Carvalho, V. O., Celli, A., BanckeLaverde, B. L., Cunico, C., Santos Piedade, G., Lucas de Mello, M., & Beirao Junior, P. S. (2016). Progeria and the early aging in children: a case report. Dermatology Online Journal, 22(2), 13030/qt7kt4f85m. - DOI - PubMed
    1. Piekarowicz, et al. (2019). Hutchinson-Gilford progeria syndrome—current status and prospects for gene therapy treatment. Cells, 8(2), 88. https://doi.org/10.3390/cells8020088 . - DOI - PubMed - PMC
    1. Harhouri, et al. (2018). An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome. Nucleus., 9(1), 246–257. https://doi.org/10.1080/19491034.2018.1460045 . - DOI - PubMed - PMC
    1. Santiago-Fernández, et al. (2019). Development of a CRISPR/Cas9-based therapy for Hutchinson-Gilford progeria syndrome. Nature Medicine, 25(3), 423–426. https://doi.org/10.1038/s41591-018-0338-6 . - DOI - PubMed - PMC
    1. Zhang, J., Lian, Q., Zhu, G., Zhou, F., Sui, L., Tan, C., Mutalif, R. A., Navasankari, R., Zhang, Y., Tse, H. F., Stewart, C. L., & Colman, A. (2011). A human iPSC model of Hutchinson-Gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell, 8, 31–45. - DOI - PubMed

LinkOut - more resources